<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072954</url>
  </required_header>
  <id_info>
    <org_study_id>ARL/CT/13/003</org_study_id>
    <secondary_id>CTRI No. CTRI/2013/11/004152</secondary_id>
    <nct_id>NCT02072954</nct_id>
  </id_info>
  <brief_title>Bioequivalence Fasting Study in Patients</brief_title>
  <official_title>A Multicentric, Open Label, Randomized, Balanced, Two Treatment, Three Period, Three Sequence, Crossover, Multiple Dose, Steady State Bioequivalence Study of Asenapine Sublingual Tablets, 10 mg Manufactured by AMNEAL PHARMACEUTICALS, USA With Reference Product SAPHRIS® (Asenapine) Sublingual Tablets, 10 mg Manufactured by Catalent UK Swindon Zydis Ltd., Blagrove, Swindon, Wiltshire, SN5 8RU, UK; Distributed by Merck Sharp &amp; Dohme Corp., a Subsidiary of Merck &amp; Co., Inc., Whitehouse Station, NJ, 08889, USA in Adult Human Male &amp; Female Patients Under Fasting Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amneal Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Accutest Research Laboratories (I) Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amneal Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare and evaluate the oral bioavailability of Asenapine Sublingual Tablets, 10 mg
      manufactured by AMNEAL PHARMACEUTICALS, USA with SAPHRIS® (asenapine) sublingual tablets, 10
      mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare and evaluate the oral bioavailability of Asenapine Sublingual Tablets, 10 mg
      manufactured by AMNEAL PHARMACEUTICALS, USA with SAPHRIS® (asenapine) sublingual tablets, 10
      mg following a multiple-dose administration in adult human patients who are receiving a
      stable twice daily dose of asenapine maleate EQ 10 mg base.

      To monitor the safety and tolerability of a multiple doses of asenapine sublingual tablets 10
      mg in adult human patients who are receiving a stable twice daily dose of asenapine maleate
      EQ 10 mg base.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0-tau</measure>
    <time_frame>Dosing interval on day 7</time_frame>
    <description>The area under plasma concentration versus time curve, over the steady state dosing interval, calculated using linear trapezoidal method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Dosing interval on day 7</time_frame>
    <description>Maximum measured plasma concentration over the steady state doing interval</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>Dosing interval on day 7</time_frame>
    <description>Minimum measured plasma concentration over the steady state dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Dosing interval on day 7</time_frame>
    <description>Time the maximum measured plasma concentration over the steady state dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg</measure>
    <time_frame>Dosing interval on day 7</time_frame>
    <description>Average calculated plasma concentration over the steady state dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Fluctuation</measure>
    <time_frame>Dosing interval on day 7</time_frame>
    <description>[Cmax - Cmin/ Cavg] x 100</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Asenapine Sublingual Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asenapine Sublingual Tablets, 10 mg. Twice daily for a period of 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saphris Subligual Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Asenapine Sublingual Tablets, 10 mg. Twice daily for 2 periods of 7 days each.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine Sublingual Tablets 10 mg</intervention_name>
    <description>White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side</description>
    <arm_group_label>Asenapine Sublingual Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine Sublingual Tablets 10 mg</intervention_name>
    <description>Round, white to off-white sublingual tablets, with &quot;10&quot; on one side within a circle</description>
    <arm_group_label>Saphris Subligual Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients of either sex with age between 18 to 65 years (both inclusive) and have
             been taking a stable dose of asenapine maleate sublingual tablet, EQ 10 mg base twice
             daily therapy for at least three months.

          -  Willing and able to comply with study visit schedule and other protocol requirements
             as indicated by signed written informed consent witnessed by a legally acceptable
             representative.

          -  Females of childbearing (who has not completed 01 year after menopause &amp; have not gone
             through hysterectomy or bilateral tubal ligation) potential must have a negative
             pregnancy test (at screening, before randomization and before check-in to housing) as
             well as must be non-lactating at screening and must agree to use an effective
             contraceptive method during study.

        Exclusion Criteria:

          -  History of allergic or adverse reactions to asenapine maleate or olanzapine as judged
             by investigator

          -  If consuming tobacco orally (spit tobacco, gutka, pan masala, pan, etc.)

          -  A history of severe hepatic impairment, drug induced leukopenia/ neutropenia,
             congenital prolongation of the QT interval, cardiac arrhythmias, myocardial infarction
             or unstable heart disease

          -  Concurrent primary psychiatric or neurological diagnosis, including organic mental
             disorder, severe tardive dyskinesia, or idiopathic Parkinson's disease

          -  Abnormal laboratory results

          -  A history of granulocytopenia or myeloproliferative disorders (drug-induced or
             idiopathic)

          -  A medical or surgical condition that might interfere with the absorption, metabolism,
             or excretion of asenapine maleate

          -  History of multiple syncopal episodes

          -  History of epilepsy or risk for seizures

          -  Any condition/ Abnormal baseline findings that in the investigators' judgment might
             increase the risk to the patient (e.g. Significant orthostatic hypotension defined as
             a drop in systolic blood pressure of 30 mm Hg or more and/or a drop in diastolic blood
             pressure of 20 mm Hg or more on standing) or decrease the chance of obtaining
             satisfactory data needed to obtain the objective of the study.

          -  A history of alcohol or drug dependence by DSM-IV criteria during the 6-month period
             immediately prior to study entry

          -  Positive tests for drug or alcohol abuse at screening or baseline

          -  Use of any of the following medication in the 14 days preceding enrollment: Strong
             CYP3A4 inhibitors, Strong CYP3A4 inducers, CYP1A2 inhibitors, Antihypertensive
             medication or any medication that might predispose to orthostatic hypotension, Drugs
             known to suppress bone marrow function, medications known to prolong the QTc interval.

          -  Participation in any other clinical study or receipt of treatment with any
             investigational drug or device within 1 month prior Screening.

          -  Blood donation/ loss exceeding 550 mL within last 90 days.

          -  Any expected changes in concomitant medications during the period of study

          -  Compliance with outpatient medication schedule not expected
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashutosh Jani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accutest Reserach laboratories (i) Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shri Hatkesh Healthcare Foundation</name>
      <address>
        <city>Junagadh</city>
        <state>Gujurat</state>
        <zip>362 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divyam Hospital</name>
      <address>
        <city>Surat</city>
        <state>Gujurat</state>
        <zip>395 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <disposition_first_submitted>June 25, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>June 25, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 27, 2014</disposition_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

